There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Ozempic, while effective for weight loss, is linked to emerging dental problems termed \"Ozempic teeth.\" Patients report dry ...

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

Weight loss jabs could reduce the risk of up to 14 types of cancer, new research has found. Mounjaro, Ozempic and other ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...